Company Overview and News
I am projecting AGNC will report a combined notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the third quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW WMC NRZ AIC CYS TRI MTGE MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC HTS IVR NYMT FMCCS FMCCT
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the third quarter of 2018.
NYMTO ORC CHMI NYMTP AI TWO AGNC AIW NRZ AIC NLY CYS ARR NYMT
We have been bearish on Arlington Asset Investment Corporation (AI) in the past. With the declining price over the last year, we are now neutral on the stock. However, there are times where their baby bonds, AIC and AIW, will come into the buy range. AI-B is their preferred share, but it is routinely overvalued by a large margin relative to the baby bonds. We view AIC as being the better baby bond right now and will focus on comparing AIC to AI-B.
AI AIC AIW
2018-10-05 seekingalpha - 2
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 10/2/18. Yields above 12.4% narrowed the list to 30.
GOV AMID GARS AIC MMLP GOVNI NAP PER HCLP CCLP AI MDLY AIW FGP USDP CBL SNMP
This series projects AGNC’s income statement for the third quarter of 2018. These projections help readers understand how most of the fixed-rate agency mREIT sector performed (valuable insight).
NYMTO ORC CHMI NYMTP AI AGNC AIW MO NRZ AIC NLY CYS ARR HTS NYMT
2018-09-24 seekingalpha - 1
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to 19 mREIT peers.
ANH NYMTO ORC CHMI NYMTP AI CIM CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
Following continued requests by readers, this article analyzes fixed-rate agency MBS price movements during the third quarter of 2018 (through 9/14/2018).
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC IVR NYMT FMCCS FMCCT
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 9/14/18. Yields above 12.2% narrowed the list to 30.
AMID AIC MMLP NAP PER HCLP CCLP AI GMLP MDLY AIW USDP SNMP
WallStars are distinguished by positive broker target price upsides. Five top net-gain financial WallStars, MDLY, BLX, GARS, CPTA, and BBVA averaged 42.29% estimated net gains per one-year targets as of September 7, 2018.
AIY CMFN TCRX AINV GARS CLA FSIC AIC GECC TCPC BVA AIB TCRD TCRZ TSLF AI OFS MDLY CPTA AIW
WallStars show positive broker target price upsides. 78 stocks displayed 10%+ forward yield, $2.50+ prices, and $50M+ market caps as of 8/31/18. Yields above 12.19% narrowed the list to 30.
JE AMID AIC MMLP NAP PER JE AI GMLP MDLY AIW USDP SNMP
2018-08-15 seekingalpha - 2
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
WallStars show positive broker target price-upsides. 66 displayed 10%+ forward yield, at $2+ prices, and $10M+ market caps as of 8/9/18. Yields above 11.88% narrowed this WallStar list to 30.
SNR.WI NGL SNR AIC MCQ MMLP MCV BBDC PER HCLP SNR MCX AI GMLP MDLY CVRR AIW SNMP MCC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET